Content
March 2016, Volume 39, Issue 3
- 251-260 A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
by Mickael Arnaud & Francesco Salvo & Ismaïl Ahmed & Philip Robinson & Nicholas Moore & Bernard Bégaud & Pascale Tubert-Bitter & Antoine Pariente - 261-270 Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology
by Christian Hampp & Patty Greene & Simone P. Pinheiro - 271-276 The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015
by Roni P. Dodiuk-Gad & Cristina Olteanu & Wen-Hung Chung & Neil H. Shear
February 2016, Volume 39, Issue 2
- 93-107 Mortality Risk of Hypnotics: Strengths and Limits of Evidence
by Daniel F. Kripke - 109-116 Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many
by Cathal A. Cadogan & Cristín Ryan & Carmel M. Hughes - 117-130 Testosterone Replacement Therapy and Mortality in Older Men
by G. I. Hackett - 131-146 Tools for Assessing Potential Significance of Pharmacist Interventions: A Systematic Review
by Thi-Ha Vo & Bruno Charpiat & Claire Catoire & Michel Juste & Renaud Roubille & François-Xavier Rose & Sébastien Chanoine & Jean-Luc Bosson & Ornella Conort & Benoît Allenet & Pierrick Bedouch - 147-157 Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
by Michael W. Dunne & George H. Talbot & Helen W. Boucher & Mark Wilcox & Sailaja Puttagunta - 159-169 Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports
by Christine Njuguna & Annemie Stewart & Johannes P. Mouton & Marc Blockman & Gary Maartens & Annoesjka Swart & Briony Chisholm & Jackie Jones & Mukesh Dheda & Ehimario U. Igumbor & Karen Cohen - 171-184 Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial
by Lauren McCormack & R. Craig Lefebvre & Carla Bann & Olivia Taylor & Paula Rausch - 185-192 Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
by Kevin Klein & Joep H. G. Scholl & Niels S. Vermeer & André W. Broekmans & Eugène P. Puijenbroek & Marie L. Bruin & Pieter Stolk
January 2016, Volume 39, Issue 1
- 1-3 What Is the Plural of a ‘Yellow’ Anecdote?
by Stephen J. W. Evans - 5-13 Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives
by Steen Husted & Freek W. A. Verheugt & Willemijn J. Comuth - 15-27 Advances in the Pharmacogenomics of Adverse Drug Reactions
by Susannah L. Collins & Daniel F. Carr & Munir Pirmohamed - 29-43 An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies
by Miguel-Angel Maciá-Martínez & Francisco J. Abajo & Gilly Roberts & Jim Slattery & Bharat Thakrar & Antoni F. Z. Wisniewski - 45-57 Feasibility of Prioritizing Drug–Drug-Event Associations Found in Electronic Health Records
by Juan M. Banda & Alison Callahan & Rainer Winnenburg & Howard R. Strasberg & Aurel Cami & Ben Y. Reis & Santiago Vilar & George Hripcsak & Michel Dumontier & Nigam Haresh Shah - 59-68 The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project
by Emanuel Raschi & Elisabetta Poluzzi & Francesco Salvo & Ariola Koci & Marc Suling & Stefania Antoniazzi & Luisella Perina & Lorna Hazell & Ugo Moretti & Miriam Sturkenboom & Edeltraut Garbe & Antoine Pariente & Fabrizio Ponti - 69-78 Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase®
by Ana Aldea Perona & Mar García-Sáiz & Emilio Sanz Álvarez - 79-87 The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study
by C. A. K. Stelt & A. M. A. Vermeulen Windsant-van den Tweel & A. C. G. Egberts & P. M. L. A. Bemt & A. J. Leendertse & W. A. J. J. Hermens & R. J. Marum & H. J. Derijks - 89-90 Comment on: “Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case–Control Study in Haryana, India”
by Sibel Yöntem & Belgin Maden-Tastan & Yusuf Cem Kaplan - 91-92 Authors’ Reply to Sibel Yöntem and Colleagues’ Comment on “Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case-Control Study in Haryana, India”
by Sutapa Bandyopadhyay Neogi & Preeti H. Negandhi & Ravi Kant Gupta & Abhijit Ganguli & Sanjay Zodpey & Amarjeet Singh & Rakesh Gupta
July 2015, Volume 38, Issue 7
- 611-620 DNA Barcoding and Pharmacovigilance of Herbal Medicines
by Hugo J. Boer & Mihael C. Ichim & Steven G. Newmaster
October 2014, Volume 37, Issue 10
- 743-759 Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum
by Jürgen Beckmann & Ulrich Hagemann & Priya Bahri & Andrew Bate & Ian Boyd & Gerald Dal Pan & Brian Edwards & I. Edwards & Kenneth Hartigan-Go & Marie Lindquist & John McEwen & Yola Moride & Sten Olsson & Shanthi Pal & Rachida Soulaymani-Bencheikh & Marco Tuccori & Claudia Vaca & Ian Wong - 761-764 Pharmacovigilance for a Revolving World: Prospects of Patient-Generated Data on the Internet
by G. Norén - 765-770 Pharmacovigilance in China: Current Situation, Successes and Challenges
by Li Zhang & Lisa Wong & Ying He & Ian Wong - 771-776 Restrictive Reimbursement Policies: Bias Implications for Claims-Based Drug Safety Studies
by Joshua Gagne - 777-790 Text Mining for Adverse Drug Events: the Promise, Challenges, and State of the Art
by Rave Harpaz & Alison Callahan & Suzanne Tamang & Yen Low & David Odgers & Sam Finlayson & Kenneth Jung & Paea LePendu & Nigam Shah - 791-804 The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis
by Jacqueline Flank & Lillian Sung & Christopher Dvorak & Wendy Spettigue & L. Dupuis - 805-813 Comparison of Pregnancy and Lactation Labeling for Attention-Deficit Hyperactivity Disorder Drugs Marketed in Australia, the USA, Denmark, and the UK
by Pernille Warrer & Lise Aagaard & Ebba Hansen - 815-829 Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
by Agata Ptaszynska & Kristina Johnsson & Shamik Parikh & Tjerk Bruin & Anne Apanovitch & James List
September 2012, Volume 35, Issue 9
- 695-709 Early Investigation of QTc Liability
by Rashmi R. Shah & Joel Morganroth - 711-724 A Pathway to Improved Prospective Observational Post-Authorization Safety Studies
by Victor A. Kiri - 725-731 A Computerized Physician Order Entry Set Designed to Improve Safety of Intravenous Haloperidol Utilization
by Andrew J. Muzyk & Sarah K. Rivelli & Wei Jiang & Heather Heinz & Amber Rayfield & Jane P. Gagliardi - 733-743 Methods for Retrospective Detection of Drug Safety Signals and Adverse Events in Electronic General Practice Records
by Andrew Tomlin & David Reith & Susan Dovey & Murray Tilyard - 745-758 Drug Interactions in Dying Patients
by Sebastian Frechen & Anna Zoeller & Klaus Ruberg & Raymond Voltz & Jan Gaertner - 759-767 Drug Fever
by Dominique Vodovar & Christine LeBeller & Bruno Mégarbane & Agnes Lillo-Le-Louet & Thomas Hanslik - 769-781 Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments
by Chen Wu & Chaim M. Bell & Walter P. Wodchis